For resource-limited startups, the most critical early investment is ensuring drug stability. A stable molecule not only improves viability for later development stages but also preserves the integrity of retained samples. These samples are invaluable for bridging studies and future analysis as the program matures.

For drugs nearing the end of their patent life, creating an improved formulation with an advanced technology can generate new drug product intellectual property. This strategy protects the asset and extends its market exclusivity long after the original molecular patent expires.

To overcome pharma's preference for new chemical entities (NCEs), Cereno created a second-generation drug by deuterating its original molecule. This modification improved the metabolite profile and, critically, made it a patentable NCE, opening doors for broader platform deals.

By reformulating existing oncology drugs, Nenology uses the streamlined 505(b)(2) regulatory pathway, de-risking and accelerating development. Simultaneously, their composition-of-matter patents provide strong intellectual property protection typically associated with entirely new chemical entities, creating a unique strategic advantage.

Apogee built its strategy around known biological mechanisms, focusing innovation solely on antibody engineering. This allowed them to de-risk assets early and efficiently (e.g., proving half-life in healthy volunteers). This clear, stepwise reduction of risk proved highly attractive to capital markets, enabling them to raise significant funds for late-stage development.

A great molecule isn't enough to attract investment. Scientists must demonstrate they've considered manufacturing from day one. Designing a robust process that fits a consistent GMP facility shows investors that the project is not just a scientific curiosity but a viable path to a scalable product.

Instead of patenting a specific molecule, Alt-Pep underwent a decade-long process to patent the novel alpha-sheet protein structure itself. This unconventional IP strategy gives them a powerful, defensible platform applicable across numerous amyloid diseases, not just a single target composition.

To commercialize a simple mixture, the company built an IP portfolio around the timing, delivery, and indications for GIK. Crucially, they secured a 'trifecta' of FDA support: Special Protocol Assessment, Breakthrough Designation, and a Biologic License Application, which grants 12 years of market exclusivity, creating a strong competitive barrier without a traditional drug patent.

For old molecules lacking composition-of-matter patents, a robust IP moat can be built by combining new use patents, patents on novel administration forms, and securing market exclusivity through Orphan Drug Designation for rare diseases.